For years, the only way to take a GLP-1 weight-loss drug was to inject it. That changed in late 2025, when the FDA cleared a 25 mg oral semaglutide tablet, sold under the Wegovy brand, making it the first pill-form GLP-1 approved for chronic weight management. Months later, as of spring 2026, the practical question millions of patients face is not whether a pill exists but whether anyone will pay for it.
Federal regulators have declined to open the door that would matter most. When the Centers for Medicare & Medicaid Services finalized its Contract Year 2026 rule, the agency dropped a draft proposal that would have let Medicare Part D and Medicaid cover anti-obesity medications for obesity treatment. The final rule preserved a longstanding statutory exclusion: Medicare still does not cover drugs prescribed solely for weight loss. The result is a widening gap between what the FDA has approved and what most patients can afford.
A pill arrives, but the price tag stays hidden
Novo Nordisk’s oral Wegovy approval came with a cardiovascular bonus. The label includes a claim for reducing major adverse cardiovascular events, or MACE, mirroring the indication the FDA had already granted to injectable Wegovy for heart-risk reduction based on a trial of roughly 17,600 participants. That cardiovascular framing is more than a clinical footnote. It gives prescribers a way to seek insurance coverage under a heart-disease indication rather than an obesity one, sidestepping plan exclusions that block weight-loss drugs.
Eli Lilly carved a similar workaround with tirzepatide. The FDA approved Zepbound as the first medication for obstructive sleep apnea in adults with obesity, based on two clinical trials. An OSA diagnosis can trigger coverage even when a health plan explicitly excludes weight-management drugs.
What neither company has done is make pricing transparent for these newer uses. Novo Nordisk has not disclosed a list price for oral Wegovy, and without that number, no one can say whether the pill will lower out-of-pocket costs or simply offer a different delivery method at a comparable price. Injectable Wegovy currently carries a list price above $1,300 a month. If the oral version lands in the same range, employers and insurers may treat it as a line extension, not a reason to broaden access.
Medicare’s half-open door
CMS did not walk away from GLP-1s entirely. The agency announced the Medicare GLP-1 Bridge, a demonstration program under the BALANCE Model set to launch in July 2026. The bridge distinguishes between indications already coverable under Part D, such as cardiovascular risk reduction and obstructive sleep apnea, and a narrower demonstration-level pathway for weight management specifically.
In plain terms: a Medicare beneficiary whose doctor prescribes a GLP-1 for documented heart disease or sleep apnea may access the drug through existing Part D channels. A beneficiary who needs the same drug purely for obesity faces a demonstration program with prior-authorization requirements and eligibility criteria that CMS has described only in general terms. Specific thresholds, including BMI cutoffs and required comorbidities, have not been fully detailed in public documents. Whether the bridge will serve tens of thousands of patients or a small pilot cohort will not be clear until enrollment data emerges after the July launch.
On Capitol Hill, the Treat and Reduce Obesity Act, which would permanently lift Medicare’s statutory exclusion of anti-obesity drugs, has been reintroduced in multiple sessions of Congress but has not reached a floor vote. Until legislation passes, the bridge program represents the furthest Medicare has gone toward covering weight-loss medications.
State Medicaid: 50 different answers
Medicaid adds another layer of complexity. Federal beneficiary resources outline general program benefits but do not require states to cover any specific anti-obesity medication. Each state sets its own formulary, prior-authorization rules, and indication requirements. Some cover injectable GLP-1s for diabetes but not for weight loss. Others have begun adding obesity indications. No centralized public database tracks which states cover oral versus injectable formulations or which labeled uses they recognize.
That patchwork creates real consequences. A Medicaid enrollee in one state may fill a Wegovy prescription with modest copays; a person with the same diagnosis across the border may have no coverage at all. The arrival of an oral option does not automatically change those state-level decisions, though it may accelerate lobbying from patient-advocacy groups pushing for broader formulary inclusion.
What no one knows yet
Several critical questions remain unanswered heading into mid-2026:
Patient preference. Will people switch from a weekly injection to a daily pill? For some, swallowing a tablet every morning beats a needle. For others, once-a-week dosing is simpler. Novo Nordisk has experience with oral semaglutide through Rybelsus, a lower-dose version approved for type 2 diabetes, but uptake patterns for a diabetes drug do not necessarily predict behavior in a weight-management population. Real-world prescription data will take months to accumulate.
Adherence. Daily dosing demands a different level of routine than weekly injections. If adherence drops, long-term effectiveness could suffer, and payers watching outcomes data may tighten coverage further. No head-to-head adherence studies comparing oral and injectable Wegovy have been published.
Commercial insurance response. Private insurers and self-funded employers cover the majority of working-age Americans, and their formulary decisions will shape access more than Medicare policy for most patients. None of the major pharmacy benefit managers have issued public statements on whether oral Wegovy or Zepbound’s OSA indication will prompt formulary changes. Historically, PBMs have used step-therapy requirements and prior authorizations to manage GLP-1 spending, and there is no signal that a new formulation will loosen those controls.
Safety at scale. As GLP-1 prescriptions climb and treatment durations lengthen, postmarketing surveillance becomes more important. The federal safety reporting portal collects reports of serious side effects from patients and clinicians, but how aggressively regulators will use that data to update labeling or coverage criteria is an open question.
Approvals keep outrunning access
The pattern playing out with GLP-1s is not new in American health care, but the scale is. The FDA has now approved these drugs for weight loss, cardiovascular risk reduction, and obstructive sleep apnea in both injectable and oral forms. The clinical menu is broader than it has ever been. Coverage, by contrast, remains tethered to statutory language written before GLP-1 receptor agonists existed, employer budgets strained by per-member costs that can exceed $15,000 a year, and state Medicaid programs making decisions one formulary meeting at a time.
For patients, the practical reality in spring 2026 is this: more drugs are approved, more indications are on the label, and a pill option now exists. But the ability to fill a prescription still depends on which insurance card is in your wallet, which diagnosis code your doctor selects, and whether your state or plan has decided this class of medication is worth covering. The regulatory landscape is moving faster than the coverage landscape, and until those two catch up to each other, access will remain uneven.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
